{"id":551255,"date":"2021-07-05T16:44:01","date_gmt":"2021-07-05T16:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=551255"},"modified":"2021-07-05T16:44:01","modified_gmt":"2021-07-05T16:44:01","slug":"cutaneous-tcell-lymphoma-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-tcell-lymphoma-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_551255.html","title":{"rendered":"Cutaneous T-cell Lymphoma Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1625475879.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cutaneous T-cell Lymphoma Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1625475879.jpeg\" alt=\"Cutaneous T-cell Lymphoma Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cCutaneous T-Cell Lymphoma (CTCL) \u2013 Pipeline Insight, 2021,\u201d report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Cutaneous T-Cell Lymphoma (CTCL) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. <\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;<strong>Cutaneous T-cell Lymphoma Pipeline Insight<\/strong>&rdquo;<\/a> report provides comprehensive insights about key companies&nbsp;and pipeline drugs in the Cutaneous T-cell Lymphoma pipeline landscapes. It comprises Cutaneous T-cell Lymphoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cutaneous T-cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cutaneous T-cell Lymphoma pipeline products.&nbsp; &nbsp; &nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Cutaneous T-cell Lymphoma Pipeline Report<\/a>&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as <\/span><span>Soligenix, Janssen, Medivir AB, 4SC AG,<\/span><span> etc., are developing therapies for the treatment of Cutaneous T-cell Lymphoma.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Emerging therapies such as <\/span><span>SGX301, Quisinostat, Remetinostat, Resminostat, <\/span><span>are expected to have a significant impact on the <\/span><span>&nbsp;Cutaneous T-cell Lymphoma <\/span><span>market in the coming years.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get an overview of pipeline landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Cutaneous T-cell Lymphoma Clinical Trials Analysis&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Cutaneous T-cell lymphoma is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help your body&#8217;s germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Cutaneous T-cell Lymphoma Emerging Drugs<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">SGX301 by Soligenix<strong>&nbsp;<\/strong><\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Quisinostat <\/span><span>by <\/span><span>Janssen<\/span><\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Remetinostat <\/span><span>by <\/span><span>Medivir AB<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>For further information, refer to the detailed report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Cutaneous T-cell Lymphoma Pipeline Therapeutics&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of Cutaneous T-cell Lymphoma Pipeline Drug Insight&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage: Global<strong>&nbsp;<\/strong><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Major Players:<\/span><span> Soligenix, Janssen, Medivir AB, 4SC AG, and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pipeline Therapies:<\/span><span> SGX301, Quisinostat, Remetinostat, Resminostat, and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma- Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Late Stage Products (Phase II\/III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Preclinical Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16&nbsp;<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous T-cell Lymphoma Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cutaneous-tcell-lymphoma-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cutaneous-tcell-lymphoma-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cCutaneous T-Cell Lymphoma (CTCL) \u2013 Pipeline Insight, 2021,\u201d report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Cutaneous T-Cell Lymphoma (CTCL) pipeline landscape. It covers the pipeline drug profiles, including clinical and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-tcell-lymphoma-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_551255.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-551255","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=551255"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551255\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=551255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=551255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=551255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}